Symphony Asset Management’s AstraZeneca AZN Stock Holding History

Symphony Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-9,695	Closed	-$658K	–	384
2015 Q4	$658K	Sell	9,695 -4,666	-32%	-$306K	0.07%	233
2015 Q3	$914K	Buy	14,361 +2,386	+20%	+$157K	0.11%	200
2015 Q2	$763K	Sell	11,975 -766	-6%	-$52.4K	0.1%	218
2015 Q1	$872K	Buy	12,741 +9,521	+296%	+$662K	0.1%	197
2014 Q4	$227K	Hold	3,220	–	–	0.03%	371
2014 Q3	$230K	Hold	3,220	–	–	0.02%	368
2014 Q2	$239K	Buy	+3,220	New	+$233K	0.02%	392
2014 Q1	–	Sell	-8,751	Closed	-$520K	–	411
2013 Q4	$520K	Buy	+8,751	New	+$475K	0.04%	274

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Symphony Asset Management's AZN Position: Q1 2016 in Review

Symphony Asset Management sold out of AstraZeneca (AZN) in Q1 2016, closing a stake of 9,695 shares — an estimated $658K sold.

Symphony Asset Management first reported a position in AZN in Q4 2013 and held it in 8 quarters. The position peaked at $914K in Q3 2015. 390 funds tracked by Wall St. Rank hold AZN as of Q1 2016.

Symphony Asset Management reported no remaining AstraZeneca position as of Q1 2016 after selling out during the quarter.
Symphony Asset Management sold 9,695 AstraZeneca shares in Q1 2016, an estimated $658K.
Symphony Asset Management first reported a position in AstraZeneca in Q4 2013 and held it in 8 quarters.
Symphony Asset Management's AstraZeneca position peaked at $914K in Q3 2015.
390 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2016.

Based on Symphony Asset Management's 13F filing for Q1 2016, filed 13 May 2016.